Related Experiment Video
Updated: Aug 16, 2025
Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles
Published on: December 22, 2023
3% Polidocanol Sclerotherapy for Pyogenic Granuloma: Efficacy and Safety Analysis
Ajay J Deshpande1, Vineet C Dubey2
1Department of Dermatology, Maharashtra Medical Foundation, Joshi Hospital, Pune, India.
Introduction:
Pyogenic granuloma is a commonly occurring inflammatory hyperplasia involving skin and mucous membranes. Various modalities of treatment have been used to treat pyogenic granuloma. However, there is an increased risk of intraoperative bleeding and recurrence of pyogenic granuloma following surgical treatment of pyogenic granuloma. Therefore, sclerotherapy has evolved as an effective alternative treatment modality in excellent safety and efficacy.
Aims And Objectives:
The aim of this study was to assess the safety and efficacy of 3% polidocanol in liquid form in pyogenic granuloma as a sclerosant.
Settings And Design:
This was a retrospective study of cases treated between March 2019 and February 2020 at two different private institutes.
Materials And Methods:
The study included 30 patients with 30 pyogenic granulomas treated with 3% polidocanol liquid. Individuals with comorbid conditions such as diabetes, hypertension, thyroid disorders, and those who were on medications were excluded from the study. Two units of 3% polidocanol solution were injected with an insulin syringe at the base of the lesion. Changes in lesions and adverse events were recorded and injections were repeated after a gap of 2 weeks if needed.
Result:
In 28 patients, there was complete resolution of the lesion within 4 weeks and 2 patients received a second injection of polidocanol. All the patients tolerated the procedure and the lesions resolved without any significant sequelae.
Discussion:
The advantages of 3% polidocanol sclerotherapy are that it is a safe, easy, effective, and minimally invasive procedure with little discomfort to the patient and very minimal complications as compared with other modalities.
Conclusion:
Polidocanol 3% solution is an effective sclerosant for the treatment of pyogenic granuloma.The aim of this study was to assess the safety and efficacy of 3% polidocanol in the liquid form in PG as a sclerosant.
Insights
Sclerotherapy using 3% polidocanol effectively treats pyogenic granuloma with minimal complications. This minimally invasive procedure offers a safe and efficient alternative to surgical removal, with high resolution rates.
Area of Science:
- Dermatology
- Dermatologic Surgery
Background:
- Pyogenic granuloma is a common skin condition requiring treatment.
- Traditional surgical treatments carry risks of bleeding and recurrence.
- Sclerotherapy offers a potentially safer and effective alternative.
Purpose of the Study:
- To evaluate the safety and efficacy of 3% polidocanol as a sclerosant for pyogenic granuloma.
Main Methods:
- A retrospective study of 30 patients with pyogenic granuloma treated with 3% polidocanol liquid.
- Exclusion of patients with comorbid conditions.
- Injection of polidocanol at the lesion base, with repeat injections if necessary.
Main Results:
- Complete resolution in 28 out of 30 patients within 4 weeks.
- Two patients required a second injection.
- The procedure was well-tolerated with no significant adverse events.
Conclusions:
- 3% polidocanol is an effective and safe sclerosant for pyogenic granuloma treatment.
- Sclerotherapy is a minimally invasive option with high efficacy.
- This method presents fewer complications compared to surgical interventions.
